Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.
- DOI
- 10.1155/2020/3208391
- Published
- 2020
- Container
- BioMed research international
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
serious concern Score 10/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- serious concernRetraction Watch retraction: 1 retraction notice matched this DOI.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1155/2020/3208391,
title = {Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.},
author = {Zhang M and Li L and Zhang S and Zhu W and Yang S and Di G and Ma X and Yang H},
year = {2020},
journal = {BioMed research international},
doi = {10.1155/2020/3208391},
url = {https://doi.org/10.1155/2020/3208391}
}RIS
TY - JOUR TI - Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study. AU - Zhang M AU - Li L AU - Zhang S AU - Zhu W AU - Yang S AU - Di G AU - Ma X AU - Yang H PY - 2020 JO - BioMed research international DO - 10.1155/2020/3208391 UR - https://doi.org/10.1155/2020/3208391 ER -
APA
M, Z., L, L., S, Z., W, Z., S, Y., G, D., X, M., & H, Y. (2020). Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.. BioMed research international. https://doi.org/10.1155/2020/3208391
Source records
- pubmed · retrieved 2026-09-25T01:02:37.639Z